期刊文献+

美国和加拿大药品风险沟通方法及其对我国的启示 被引量:7

Drug risk communication method of America and Canada and its implication in China
原文传递
导出
摘要 文中介绍了美国食品药品监督管理局(FDA)和加拿大卫生部(HC)对药品风险沟通的认识及其风险沟通的方法。FDA和HC已有十分完善的药品风险沟通方法,而我国在这方面基础还比较薄弱,可借鉴FDA和HC的经验,据此提出完善我国药品风险沟通现状的建议。 This article introduced drug risk communication method of US FDA HC have applied many consummate drug risk communication methods, while the drug and Canada HC. FDA and risk communication is still very weak in China. We should learn from FDA and HC experience. Here, we provided suggestions to the develop ment and improvement of Chinese drug risk communication
作者 李姗 杨悦
出处 《中国新药杂志》 CAS CSCD 北大核心 2012年第18期2104-2108,共5页 Chinese Journal of New Drugs
关键词 美国 加拿大 风险沟通 方法 工具 America Canada risk communication method tool
  • 相关文献

参考文献7

  • 1宁艳阳,杨悦.《FDA风险沟通战略计划》简介及其对我国的启示[J].中国新药杂志,2010,19(18):1648-1651. 被引量:6
  • 2HC. Description of current risk communication documents for marketed health products for human use [ EB/OL ]. [ 2011 - 02 - 25 ]. http://www, hc-sc, gc. ca/dhP-mps/pubs/medeff/guide/ 2008-risk-risques comm_guid-dir/index-eng, php.
  • 3FDA. FDA strategic plan for risk communication [ EB/OL ]. [2010 - 03 - 15 ]. http://www, fda, gov /downloads/About FDA /Reports Manuals-Forms/Reports /UCM183683. pdf.
  • 4FDA. Drug safety information-FDA's communication to the public [ EB/OL]. [ 2011 -02 -25 ]. http://www, google, com. hk/ search? q = Drug + Safety + Infor-mation + % A8CFDA% Al% AFs + Communication + to + the + Public&search-radio = on& newwin- dow = 1 &ie = gb2312&hl = zh-CN&client = aff-360daohang.
  • 5HC. Post-market risk communications for drug products [ EB/ O L ]. [ 2011 - 02 - 25 ]. http ://26448. vws. magma, ca/dhP-mps/ hmnologation-licensing/docs/cornmun-ris/commun-ris01 -eng. php.
  • 6戴秋萍,杨悦.美国药品风险沟通及其对我国的借鉴意义研究[J].中国药房,2010,21(17):6.
  • 7郭晓昕,武志昂,张承绪.药品风险管理中的信息沟通[J].中国药物警戒,2008,5(1):12-13. 被引量:22

二级参考文献8

  • 1[1]IOM.The Future of Drug Safety:Promoting and Protecting the Health of the public[EB/OL].2006-9-22[2007-10-11].http://www.iom.edu/CMS/3793/26341/37329.aspx.
  • 2[2]EMEA.Guidance for Industry-Issuance of Health Professional Communications and Public Communications by Market Authorization Holders,2005[EB/OL].2005-11-1[2007-10-15].http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/index_e.html.
  • 3[3]FDA.Guidance Drug Safety Information-FDA's Communication to the Public,2007[EB/OL].2007-5-2[2007-10-15].http://www.fda.gov/cder/guidance/index.htm.
  • 4FDA. FDA's strategic plan for risk communication[ EB/OL]. [2010 - 03 - 15 ]. http://www, fda. gov/downloads/AboutFDA/Reports- ManualsForms/Reports/UCM 183683. pdf.
  • 5FDA. Risk Communication advisory committee[ EB/OL]. [2010 - 03 - 15 ]. http ://www. fda. gov/oc/advisory/OCRCACACpg, html.
  • 6宁艳阳,杨悦.FDA风险沟通战略计划简介[N].中国医药报(法制周刊),2010-01-16(A06).
  • 7FDA. Information on heparin [ EB/OL]. [ 2010 - 03 - 15 ]. http://www, fda. gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm112597, htm#qa.
  • 8唐钧.风险沟通的管理视角[J].中国人民大学学报,2009,23(5):33-39. 被引量:46

共引文献26

同被引文献63

  • 1曹立亚,陈易新,沈璐.关于我国药品不良反应监测技术工作发展方向的思考[J].中国药物警戒,2004,1(2):3-6. 被引量:34
  • 2龚时薇,张亮,黄杰敏,詹学锋,姜卫,王成江.药品安全与风险管理[J].中国药房,2007,18(22):1687-1690. 被引量:45
  • 3国家食品药品监督管理总局.国家药品不良反应监测年度报告(2013年)[EB/OL].2014-05-14.http://www.sds.gov.en/WS01/CL0078/99794.html.
  • 4FDA. MERIDIA (sibutramine hydrochloride monohydrate) cap- sules CS-IV [ EB/OL ]. [ 2010 - 08 - 10 ]. http://www, fda. gov/downloads/drugs/drugsafety/postmarketdrugsafetyinforma- tionforpatientsandproviders/drugsafetyinformationforheath- careprofessionals/ publicheahhadvisories/ ucm1307 4 5 . pdf.
  • 5WHO. Obesity and overweight[ EB/OL]. [ 2015 - 01 - O1 ]. ht- tp : Y/www. who. int/mediacentre/factsheets/fs311/en/.
  • 6生物谷.30亿减肥药市场等待重新分羹[EB/OL].[2010—11—17].http://news.bioon.com/article/6459346.html.
  • 7FDA. FDA briefing document: AERS MI + stroke data[ EB/OL]. [2009 - 12 - 17 ]. http://www, fda. gov/downloads/Advisory- Committees/CommitteesMeetingMaterials/Drugs/Endocrinologi- candMetabolieDrugsAdvisoryCommittee/UCM225570, pdf.
  • 8国家食品药品监督管理总局.药品不良反应信息通报(第25期)关于西布曲明的最新国际安全性信息[EB/OL].[2010—02—26].http://www.sfda.gov.cn/WS01/CL0078/46365.html.
  • 9FDA. Food and drug administration amendments act of 2007 [ EB/OL ]. [ 2007 - 09 - 27 ]. http://www, gpo. gov/fdsys/ pkg/PLAW-110pub185/html/PLAW-110pub185, htm.
  • 10FDA. Cardiovascular outcomes review with use of meridia [ EB/ OL]. [2010 -01 - 11 1. http://www, fda. gov/downloads/Ad- visoryC ommittees/CommitteesMeetingM aterials/Drugs/Endocri- nologicandMetabolicDrugsAdvisoryCommittee/UCM225570, pdf.

引证文献7

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部